{
  "docId": "019de075-03fc-75b4-9b20-1ad4baba72b2",
  "docSlug": "9cc11288f450409d9a3eef75fc694943",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 39,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "balanced",
  "nDataPoints": 6,
  "notes": "The slide highlights the clinical need for new therapies due to resistance mutations (G2032R) and CNS involvement.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-03fc-75b4-9b20-1ad4baba72b2/10",
  "deckHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2",
  "deckJsonHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2.json",
  "deckAnchorHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.02,
        "w": 0.51,
        "x": 0.076,
        "y": 0.895
      },
      "kind": "source-note",
      "text": "Sources: Lin et al., J Thorac Oncol 2017; Gainor et al, JCO Precision Oncol 2017; Ou and Zhu Lung Cancer 2019; Patil et al, JTO 2018",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31c48a3b-b14b-4c86-ba31-b6197a49f3d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.495,
        "w": 0.864,
        "x": 0.068,
        "y": 0.305
      },
      "kind": "table",
      "text": "Line of Therapy, Sub-population, Incidence (US), CNS Disease, Standard of Care (2022)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e4bc2086-014b-4536-8651-9972f1e893bb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.685,
        "x": 0.076,
        "y": 0.185
      },
      "kind": "title",
      "text": "Emerging resistance mutations and increasing CNS involvement limit utility of approved therapies",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b51ee58-947a-4c8a-b31b-c0a1aa0d3f3b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.415,
        "x": 0.076,
        "y": 0.115
      },
      "kind": "title",
      "text": "ROS1-positive NSCLC Market Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "24ae455f-6e2c-424d-a07d-2c7b287a3c6e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "2440c0ac-db56-43cc-9834-56b974e25f6f",
      "evidence": "table/data: Line of Therapy, Sub-population, Incidence (US), CNS Disease, Standard of Care (2022)",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "market-segmentation-pyramid",
      "slug": null,
      "matchId": "e5557d6e-d829-425d-821f-11a6fd1788fa",
      "evidence": "Segments market by line of therapy and mutation status",
      "confidence": 0.7
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 10,
      "beatId": "b98b1b24-926a-48e2-9515-38f207bc6589",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The document provides market sizing information for ROS1-positive NSCLC.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 26,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "fe9c6514-22f1-4979-9b36-391b44fa3c8a",
      "evidence": "The document presents the limitations of current therapies and the potential benefits of Nuvalent's targeted therapies.",
      "position": 0,
      "objective": "The cost of inaction in addressing kinase resistance and selectivity challenges",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}